The common rules for circulation of drugs and medical products for members of the Eurasian Economic Union (EAEU): Russia, Armenia, Belarus, Kazakhstan and Kyrgyzstan, came into effect in May 2017. By 2025, a common drug and medical products market will be created in the five EAEU countries; by that time the rules for manufacture and sale of drugs and medical products should be completely standardized. At the same time, the national pharma industries of the EAEU countries are at different stages of development, which affects decisions adopted by the EAEU members on various integration issues. Preparation of the EAEU Action Plan (Programme) for manufacturing medical products has been on its way since 2020. This includes a plan to implement measures for stimulating manufacture of drugs and medical products in the EAEU, among them subsidies and tariff regulations, as well as government procurement support. This plan is aimed at synchronizing activities of the EAEU members on issues of support for their own pharma industries. What is the contribution and potential of Russian manufacturing in the EAEU countries for development of the industry? What successful experience of EAEU members protectionist policy can be highlighted as related to measures for support of the national pharma industry in government bidding? Manufacture of what strategically important drugs must be ensured on full-cycle principle in the EAEU? What should be the measures of government support for the national pharma industry (subsidies, reduction of customs duties, or priority access to the government procurement market)?